Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04735913
Other study ID # 20201010
Secondary ID
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date May 5, 2020
Est. completion date July 1, 2022

Study information

Verified date December 2021
Source Zhongnan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. To explore the relationship between the changes of plasma concentration of abiraterone acetate after taken orally on fasting or postprandial and gene polymorphism. 2. Study of drug Metabolite profiling after oral administration of abiraterone acetate on fasting and postprandial in Chinese adults.


Description:

Prostate cancer is the most common malignancy in men currently, second only to lung cancer in China. And in Europe and America, it has already overtaken lung and bowel cancer and become the greatest threat of of men's health. After the diagnosis of high-risk prostate cancer patients, endocrine therapy is still the main treatment. It is effective for most patients who receive androgen deprivation therapy at first. However, after the remission whose median time is 18 to 24 months through endocrine therapy, most patients will turn to castration resistant prostate cancer (CRPC). The treatment of CRPC has always been a difficult point , and now it has become the emphasis of new endocrine drug development for prostate cancer. Abiraterone acetate tablets in combination with prednisone apply to the treatment of metastatic castration-resistant prostate cancer. It has been approved by the US Food and Drug Administration in 2011 and gotten listing license in China. Abiraterone acetate is an effective irreversible inhibitor CYP17 enzyme and can be converted into abiraterone in vivo. Abiraterone is an androgen biosynthesis inhibitor with a high affinity and selectivity to CYP17. The inhibitory activity of abiraterone for CYP17 was 10-30 times higher than that of ketoconazole. Androgen biosynthesis is inhibited by inhibiting CYP17. The results of many large-scale clinical trials showed that abiraterone acetate could effectively prolong survival time of the patients . In this study, Blood and plasma samples, urine and faeces samples in 72h from healthy Chinese adult volunteers who have taken abiraterone acetate tablet orally on an empty stomach or after meals were collected for metabolite analysis, the relationship between plasma concentration and gene polymorphism, and identifying the major metabolites in metabolic biological samples to reveal the pharmacokinetic characteristics of abiraterone acetate tablets,demonstrate the pharmacodynamic mechanism,and explore the effect of different genotypes Pharmacokinetic characteristics in healthy Chinese adults. The result provides theoretical basis for clinical rational drug use.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 81
Est. completion date July 1, 2022
Est. primary completion date August 20, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age: Healthy male subjects aged 18 to 65 years - Weight: weight =50.0kg, 19 = BMI = 26 kg/m2, BMI=weight (kg) / height2(m2) - Fully aware of the purpose, nature, method and possible adverse reactions of the study, and sign informed consent prior to the commencement of any study procedure on a voluntarily base. - Be able to communicate well with the investigator and understand and abide by the terms of the study requirements. Exclusion Criteria: - Clinical laboratory examination is abnormal and clinically significant. - Vital signs examination is abnormal and clinically significant, or there are other diseases of clinical significance(Including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardio-cerebrovascular disease)or other specific systemic disease. - Electrocardiogram is abnormal and clinically significant. - HbsAg, Anti - HCV, TPPA, or HIV antibody positive. - History of allergy to abiraterone acetate tablets or its ingredients and analogs - The number of daily smoking >5 during 3 months before the trial. - Alcoholics or regular drinkers in the 6 months prior to the trial, that is drinking more than 14 units per week (1 Unit =360mL beer or 45mL 40% liquor or 150mL wine) - Positive for drug, has a history of drug abuse in the past five years or has used drugs in the 3 months prior to the trial. - Positive for alcohol screening or use of any alcoholic product within 24 hours prior to taking the study drug. - Blood donation or massive blood loss within 3 months prior to taking the study drug (>450mL). - Take any xanthine rich beverage, food, grapefruit fruit or products that contain grapefruit in 48 hours before the trial. - Take in chocolate or any food or drink containing caffeine in 48 hours before the trial. - A history of dysphagia or any gastrointestinal disease that affect drug absorption. - Have taken the study drug or participated in the drug or medical device within three months before this trial. - There are major changes in diet or exercise habits recently. - Acute disease occurs during the study screening phase or prior to taking study drugs. - There are drug combination of CYP3A4, P-GP, or Bcrp inhibitors or inducers (such as itraconazole, ketoconazole, dronedarone et al.), or any drugs that affect hepatic microsomal enzyme activity during the 28 days before taking the study drug. - Accompanied by any coagulation disorders (such as Willebrand's disease or hemophilia) or history of hemorrhagic disease. - Accompanied by any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, stomach or duodenal ulcers, etc. - Special requirements on diet and fails to comply with the diet provided and the corresponding regulations, especially for the lactose intolerant. - History of asthma or seizures. - Have a pregnancy plan in 6 months, sperm or egg donation, or reluctance to use one or more non-drug contraceptives during the trial. - Taking any prescription drugs, nonprescription drug, over-the-counter, vitamin products, or herbal medicines in 14 days before taking the study drug. - Patients with abnormal nucleic acid or antibody detection of COVID-19 and considered ineligible by the investigator. - Pulmonary CT were abnormal and considered inappropriate to participate in the study by the investigator. - Subjects considered to have poor compliance or have any factors that would make them inappropriate to participate in the study.

Study Design


Intervention

Drug:
Abiraterone acetate tablets
Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.

Locations

Country Name City State
China Zhongnan Hospital of Wuhan University Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Zhongnan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentrations of abiraterone in plasma -1h, 30min, 1h , 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h after administration for blood sampling 2 months
Primary Cmax peak concentration 2 months
Primary AUC0-t Area under curve. The linear trapezoid method is used to calculate the blood drug concentration from zero to the last measurable concentration area under the curve 2 months
Primary AUC0-8 The area under the blood concentration-time curve from zero to infinite blood concentration 2 months
Primary ?z End phase elimination rate constant, the least square method is used to find the slope of the optimal curve for phase elimination And multiplied by 2.303 2 months
Primary T1/2z Elimination or final half-life, 0.693/?z 2 months
Primary AUC_%Extra [(AUC0-8- AUC0-t)/ AUC0-8]×100%, Percentage of residual area 2 months
Primary Vz/F apparent volume of distribution, Vz/F = CLz/F /?z 2 months
Primary CLz/F apparent clearance, CLZ /F= administration dose /AUC0-8 2 months
Primary the main metabolite of abiraterone The plasma, urine and feces samples were collected to assay the metabolic profile of abiraterone in vivo by UFLC-Q-Exactive Orbitrap HRMS system 2 months
Primary genotyping related to abiraterone metabolism Mutation sites of transporter and metabolic enzyme related to abiraterone metabolism were detected through the gene detection technology service platform 10 months
See also
  Status Clinical Trial Phase
Completed NCT04531150 - Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects Phase 1
Completed NCT03437265 - A Pharmacokinetic Study of PLENVU® in Healthy Subjects Phase 1
Completed NCT03979989 - Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol) Phase 1
Completed NCT00743912 - Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers Phase 1
Not yet recruiting NCT05367011 - Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
Completed NCT06126562 - A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects Phase 1
Completed NCT00745264 - Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise Phase 1
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A
Completed NCT01082796 - Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects N/A
Terminated NCT02696954 - Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects Phase 1/Phase 2
Recruiting NCT03714568 - Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants. Phase 1
Recruiting NCT04080895 - Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects Phase 1
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT00681395 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium Phase 1
Completed NCT04617509 - A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Phase 1
Terminated NCT03059511 - Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants Phase 1
Withdrawn NCT05938608 - A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Phase 1
Completed NCT01091532 - A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. Phase 1
Completed NCT03951402 - Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women Phase 1
Completed NCT03882762 - A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol Phase 1